

Alprostadil (prostaglandin E1)

Section

Medicines administered to the neonate [c]
 Parenteral > General injections > IV: 0.5 mg per mL in alcohol

Indications

Other specified congenital anomaly of great arteries including arterial duct

Beractant

Section

Medicines administered to the neonate [c]
 Respiratory > Suspension: 25 mg per mL for intratracheal instillation

Indications

Respiratory distress syndrome of newborn

Caffeine citrate

Section

Medicines administered to the neonate [c]
 Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
 Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)

Indications

Apnoea of newborn

Carbetocin

Section

Uterotonics
 Parenteral > General injections > IV: 100 µg per mL (heat stable)

Indications

Postpartum haemorrhage

Chlorhexidine

Section

Medicines administered to the neonate [c]
 Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
 Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)

Indications

Omphalitis of newborn

Clomifene

Section

Ovulation inducers
 Oral > Solid: 50 mg (citrate)

Indications

Female infertility without specification whether primary or secondary

Condoms

Section

Barrier methods

-

Indications

Contact with health services for contraceptive management

Copper-containing intrauterine device

Section

Intrauterine devices

-

Indications

Contact with health services for insertion of contraceptive device

Dexamethasone

Section

Other medicines administered to the mother

Parenteral > General injections > unspecified: 4 mg per mL
(dexamethasone phosphate (as sodium))

Indications

Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

Diaphragms

Section

Barrier methods

-

Indications

Contact with health services for contraceptive management

Dinoprostone (prostaglandin E2)

Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 1 mg per mL

Indications

Other specified congenital anomaly of great arteries including arterial duct

Therapeutic equivalent to alprostadil (prostaglandin E1) pour

Other specified congenital anomaly of great arteries including arterial duct

Ergometrine

Section

Uterotonics

Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule
(hydrogen maleate)

Indications

Postpartum haemorrhage

Estradiol cypionate + medroxyprogesterone acetate

Section

Injectable hormonal contraceptives
Parenteral > General injections > IM: 5 mg + 25 mg

Indications

Contact with health services for reasons associated with reproduction

Ethinylestradiol + etonogestrel

Section

Intravaginal contraceptives
Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

Indications

Contact with health services for contraceptive management

Ethinylestradiol + levonorgestrel

Section

Oral hormonal contraceptives
Oral > Solid: 50 µg + 250 µg [4]
Oral > Solid: 30 µg + 150 µg

Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Ethinylestradiol + norethisterone

Section

Oral hormonal contraceptives
Oral > Solid: 35 µg + 1 mg

Indications

Contact with health services for contraceptive management

Etonogestrel-releasing implant

Section

Implantable contraceptives
Implant > Subdermal: 68 mg single rod

Indications

Contact with health services for insertion of contraceptive device

Ibuprofen

Section

Medicines administered to the neonate [c]
Parenteral > General injections > IV: 5 mg per mL

Indications

Patent arterial duct

Indometacin

Section

Medicines administered to the neonate [c]

Indications

Therapeutic equivalent to *ibuprofen* pour

Patent arterial duct

Letrozole

Section

Ovulation inducers

Oral > Solid > dosage form: 2.5 mg

Indications

Female infertility without specification whether primary or secondary

Levonorgestrel

Section

Oral hormonal contraceptives

Oral > Solid: 750 µg [2]; 1.5 mg [1]

Oral > Solid: 30 µg

Intrauterine devices

Intrauterine system with reservoir containing 52 mg of levonorgestrel.

Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Contact with health services for insertion of contraceptive device

Levonorgestrel-releasing implant

Section

Implantable contraceptives

Implant > Subdermal: 75 mg per rod (two-rods)

Indications

Contact with health services for insertion of contraceptive device

Medroxyprogesterone acetate

Section

Injectable hormonal contraceptives

Parenteral > General injections > IM: 150 mg per mL in 1 mL vial

Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system

Indications

Contact with health services for reasons associated with reproduction

Methylergometrine

Section

Uterotonics

Indications

Therapeutic equivalent to ergometrine pour

Postpartum haemorrhage

Mifepristone - misoprostol

Section

Medicines for medical abortion

Oral > Solid > tablet: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package

Indications

Unspecified time of fetal death, cause not specified

Induced abortion

Misoprostol

Section

Uterotonics

Local > Vaginal > tablet: 25 µg

Oral > Solid: 200 µg

Medicines for medical abortion

Oral > Solid > tablet: 200 µg

Indications

Unspecified obstetric condition

Postpartum haemorrhage

Spontaneous abortion, incomplete, without complication

Multiple micronutrient supplement

Section

Other medicines administered to the mother

Tablet containing:

Vit A: 800 mcg retinol activity equivalent

Vit C: 70 mg

Vit D: 5 mcg (200 IU)

Vit E: 10 mg alpha tocopherol equivalent

Vit B1: 1.4 mg

Vit B2: 1.4 mg

Vit B3: 18 mg niacin equivalent

Vit B6: 1.9 mg

Folic acid: 400 mcg

Vit B12: 2.6 mcg

Iron: 30 mg

Iodine: 150 mcg

Zinc: 15 mg

Selenium: 65 mcg

Copper: 2 mg

Indications

Maternal care for other specified conditions predominantly related to pregnancy

Nifedipine

Section

Antioxytocics (tocolytics)

Oral > Solid: 10 mg (immediate-release)

Indications

Preterm labour without delivery

Norethisterone

Section

Oral hormonal contraceptives

Oral > Solid: 350 µg

Indications

Contact with health services for contraceptive management

Norethisterone enantate

Section

Injectable hormonal contraceptives
Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

Indications

Contact with health services for reasons associated with reproduction

Oxytocin

Section

Uterotonics
Parenteral > General injections > unspecified: 10 IU per mL

Indications

Postpartum haemorrhage

Porcatant alfa

Section

Medicines administered to the neonate [c]
Respiratory > Suspension: 80 mg per mL for intratracheal instillation

Indications

Respiratory distress syndrome of newborn

Progesterone vaginal ring

Section

Intravaginal contraceptives
Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

Indications

Contact with health services for contraceptive management

Tranexamic acid

Section

Other medicines administered to the mother
Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

Indications

Postpartum haemorrhage

Ulipristal

Section

Oral hormonal contraceptives
Oral > Solid: 30 mg tablet (ulipristal acetate)

Indications

Contact with health services for postcoital contraception